Background: Tyr-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) and Tyr-Tic-Ala were the first peptides with 6 opioid antagonist activity lacking Phe, considered essential for opioid activity based on the N-terminal tripeptide sequence (Tyr-D-Xaa-Phe) of amphibian skin opioids. Analogs were then designed to restrain the rotational flexibility of Tyr by the substitution of 2,6-dimethyl-L-tyrosine (Dmt).
INTRODUCTION
Despite the advancements made with the endogenous mammalian enkephalin analogs (1, 2) , the amphibian opioid peptides, the dermorphins (p. tioned between two aromatic centers, contained the essential residues for interaction with opioid receptors. Structure-activity studies focusing on this portion of the dermorphins/deltorphins suggested pivotal roles for the aromatic side-chains of Tyr' and Phe3 (11) (12) (13) (14) (15) , leading to the tri-and tetrapeptide antagonists containing 1,2,3,4-tetrahydro-3-isoquinoline carboxylate (Tic) at position 2 and Phe at position 3, or 3 and 4 (16, 17) .
The first peptides lacking Phe that exhibited opioid activity included the minimal dipeptide H-Tyr-Tic-NH2 and the tripeptides containing Ala3, H-Tyr-Tic-Ala-OH and H-Tyr-Tic-Ala-NH2 (18) . This novel dipeptide not only adopted a low energy conformation similar to the nonpeptide N-methyl-naltrindole and shared its 8 antagonistic activity (18) . To further amplify receptor and antagonist properties of the Tyr-Tic peptides, we introduced 2',6'-dimethyl-L-tyrosine (Dmtl) to further restrain the Tyr residue that yielded a series of remarkable opioidmimetic compounds with exceptionally high affinity and ultraselectivity for 8 opioid receptors. These unusual analogs surpass the 6 selectivity of all opioid peptides known to date, including the TIP and TIPP antagonists (16, 17) and other methylated analogs (19) (20) (21) (22) by orders of magnitude. The results unveil a new model for exceedingly active opioid antagonists with potential clinical and therapeutic applications.
MATERIALS AND METHODS
Materials H-Dmt-OH, supplied by John H. Dygos, was synthesized by an asymmetric method (23) . NaFmoc-Tic and Fmoc-Ala-PEG-PS were from Advanced ChemTech (Lexington, KY, U.S.A.), and Fmoc-PAL-PEG-PS from Millipore (Waltham, MA, U.S.A.), [3HIDPDPE (34.3 Ci/mmol) and [3H] bremazocine (25.4 Ci/mmol) were products of NEN-Dupont (Billerica, MA, U.S.A.), and
[3H]DAGO (60. Peptide Synthesis Tyr-and Dmt-containing peptides were synthesized by solid phase and solution techniques. Using solid phase methods, the peptide acids and amides were synthesized using Fmoc-PAL-PEG-PS resin (0.18 mmol/g, 0.09 mmol) and Fmoc-Ala-PEG-PS (0.13 mmol/g, 0.065 mmol). NaFmoc-Tic-OH and NaFmoc-Ala-OH were used in the coupling reactions while Dmt was protected as N'Boc-Dmt-OH as reported by Chandrakumar et al. (24) . Amino acids were coupled for 1 hr in 4-fold excess diisopropylcarbodiimide in the presence of 4-fold excess 1-hydroxybenzotriazole. In the Dmt-Tic acylation step, double coupling was required; the acylating agent employed, PyBrop, occurred in the presence of 4-fold excess N-methylmorpholine. All peptides were prepared in a Milligen 9050 synthesizer and crude deprotected peptides (88% TFA, 5% water, and 7% triethylsilane) were purified by preparative HPLC.
In the solution synthesis of peptides, dipeptide acids were prepared by condensing BocDmt-OH or Boc-Tyr-(But)-OH with H-L-TicOBut or H-D-Tic-OBut, previously esterified as reported (25) with DCC/HOBt. The dipeptide alcohol (compound 5, Table 1 ) was prepared by condensing Boc-Dmt-OH and Tic-CH2-OH as given above, while 3-(hydroxymethyl)-3,4-dihydroisoquinoline (H-Tic-CH2-OH or H-Tic-ol) was synthesized according to Yamaguchi et al. (26) . Boc, But, and OBut were removed with 95% TFA at 0°C and crude peptides purified by preparative HPLC. As reported by Marsden et al. (27) , Tyr-Tic sequence, depending on the conditions, evolved to diketopiperazine. Dmt-Tic sequence also gave cyclic dipeptide; we could estimate by HPLC (Vidac C18 218 TP 5415, 5 ,um particle column [4.5 x 175 mm] using mobile phases A, 10% acetonitrile in 0.1% TFA, and mobile phase B, 60% acetonitrile in 0.1% TFA; linear gradient from 0% B to 100% B at a flow rate of 1 ml/min in 25 min at 220 nm) from the solid material after 1 month at room temperature resulted in 2.5% cyclic dipeptide, while after 36 hr in solution B at room temperature diketopiperazine formation was 55%; after 1 month in DMSO/water (90:10, v/v), less than 5% diketopiperazine was observed. 5 ,um particle column (4.5 x 175 mm) and equipped with a Bruker LC 313 UV variable wavelength detector. Recording and quantification were accomplished with a chromatographic data processor coupled to an Epson computer system (QX-10). Analytical determinations and capacity factor (K') of the peptides were determined using HPLC conditions in the above solvent systems in a linear gradient from 0% to 100% B in 25 min at a flow rate of 1 ml/min. All analogs showed less than 1% impurities when monitored at 220 nm.
679
TLC was conducted using the following solvent systems: (A) 1 -butanol/HOAc/H20 (3:1:1); and (B) EtOAc/pyridine/HOAc/H20 (6:2:0.6:1.1). Ninhydrin (1 %, Merck), fluorescamine (Hoffman-La Roche) and chlorine reagent were used as detection sprays. A compilation of the analytical properties of the peptides are listed in Table 1 .
Receptor Binding Analyses Rat membrane synaptosome preparations (P2 fraction) were prepared as detailed previously, Table 4 revealed that the goodness-of-fit to 6 receptor subsites by H-Dmt-Tic-OH (Fig. 1 ) and H-Dmt-Tic-NH2 were distinctly different than those of H-Dmt-Tic-ol, H-Dmt-Tic-Ala-OH (Fig. 1) , and H-Dmt-Tic-Ala-NH2. Hill coefficients (ii) for H-Dmt-Tic-OH (peptide 1) and H-Dmt-Tic-NH2 (peptide 2) best fitted a simple bimolecular, one-site binding model characterized by a qr approximately 1.00. H-DmtTic-ol (peptide 5), H-Dmt-Tic-Ala-OH (peptide I 1), and H-Dmt-Tic-Ala-NH2 (peptide 12) better fitted a heterogeneous two-site receptor binding model (Tj < 0.850 with p < 0.0001 in the F test) ( Table 4 ). The comparative displacement curves for H-Dmt-Tic-OH and H-Dmt-Tic-Ala-OH binding to one-and two-site models are illustrated in Fig. 1 .
Functional Bioassays
Pharmacological bioactivity determined with mouse vas deferens indicated that peptides 1, 2, 5, 11, and 12 exhibited 6 antagonist activity as observed with other Tic2 -containing peptides (16) (17) (18) . The pA2 values compare favorably to the nonpeptide antagonist natrindole (Table 5) ; however, in comparison to naltrindole, Dmt-Tic peptides are completely inactive in eliciting an agonist response with guinea-pig ileum, further substantiating the remarkable selectivity observed with these peptides in binding brain membrane receptors (Table 2) . (24, 45) . The increased 6 selectivity observed in C-terminal deamidation is consistent with the role of charged groups of the "membrane-assisted receptor selection" hypothesis (46) ; however, the magnitude of the change is so great that it must reflect constitutional and conformational modifications of the ligand as well.
The low 61K and ,u/K selectivities suggest weak affinities for the K ligand-binding domain. To ensure stringent criteria in the assessment of K receptors, due to the high affinity towards 8 receptors, ,uM concentrations of DAGO and DPDPE were employed rather than nM quantities (29-31,33) since [3H]bremazocine interacts with multiple receptor binding sites (47) .
Several constituents of opioid peptides play significant roles in securing or stabilizing the peptide within the receptor, including the N- 
... \C \C (7) . On the other hand, these residues may be involved in extensive internal H bonding which would have a major impact on the solution conformation of the peptide (6, 36, 48) . C-terminal amidation in Dmt-Tic opioidmimetic peptides increased association toward ,u receptors (Table 2) , a phenomenon consistently observed with deltorphin heptapeptide analogs (4, 40, 43) : ,u binding is enhanced by an overall increase in positive charge as seen in cyclic dermorphin analogs ( 11) and deltorphins (addition of amine groups or a C-terminal amide) (40, 42) . Although the Tyr hydroxyl group assumes an important auxiliary function in flexible opioids, the substitution by Phe 1 (2) and nonaromatic ring compounds (1 3) reduced, but did not eliminate, binding to opioid receptors, consistent with the interaction of the rigid fentanyl nonopioid agonist which lacks hydroxyl groups (49) . The chirality of the a carbon at position 2 (Table 2) is critical for opioid activity (2, 11, 14, 16) , which indicates that the ligand-binding domain of and ,u receptors differ significantly (16) . The change in chirality from L-to D-Tic abolished high affinity while simultaneously increased affinity to yield peptides with either reduced 8 The incorporation of unnatural heterocyclic amino acids in the N-terminal region of opioid peptides was implemented to reduce conformational flexibility, restrain secondary structure, and determine the influence of Phe3 in deltorphin I on activity (12, 15) . Substitution by Tic, among other bicyclic residues (15, 51) , yielded peptides with modest receptor binding properties; however, the incorporation of D-Tic into somatostatin, a nonopioid peptide whose analogs evoke an opioid response-based on the initial observations of Terenius (56)-produced a selective and potent ,u antagonist (57) . The cyclic analogs in the N-terminal tetrapeptide series of deltorphin II (H-Tyr-D-Ala-Phe-Glu), in which Phe3 was replaced by Tic led to an assortment of analogs with distinct properties toward ,u receptors (12) comparable to those of [Tic3]dermorphin (50, 51) .
Receptor binding analyses with position 4-substituted deltorphin analogs provided evidence of fits to either one-or two-site models that might represent the possible interaction with the pharmacologically defined 81 and 82 receptor subtypes, respectively (36) . In fact, cDNA cloning experiments have defined a 8 receptor distinct from p. and K receptors and it appears to correspond to the 62 subtype according to bioassay paradigms (58, 59) . A theoretical model to account for the action of agonists and antagonists (60) might also explain this phenomenon; however, neural and peripheral tissues might contain distinct populations of 8 receptors, a fact that might explain the differences observed in the K; and KRe values throughout the literature. Our bioassay data (Table 5) demonstrates that the Dmt-Tic opioidmimetic peptides exhibit antagonistic properties in vitro to a greater extent than the nonopioid compound naltrindole and that peptide 1I also possesses antagonistic activity in vivo (R. Guerrini et al., submitted).
In summary, our opioidmimetic peptides can serve as the pivotal prototypic molecules for designing a new generation of unique opioid antagonists with potential therapeutic applications. As far as the specific message domain requirements are concerned, we conclude that Dmt-Tic, and to a lesser degree Tyr-Tic, represent the ideal universal simulation of the constitutional and conformational requirements of 8 antagonists for the recognition site (message ligand-binding domain) of opioid receptors.
